Caligan Partners LP
CIK 1727492 · last filed 2025-06-02
Caligan Partners LP is a corporate insider who has filed 15 SEC Form 4 insider transactions across 4 companies since 2020. The most recent filing, for EXEL, was dated Jun 2, 2025. Across all open-market trades the lifetime net is +$15.9M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $381.8M across reported positions. The firm reports its address in New York, NY. 38 SEC filings were submitted jointly with David Edward Johnson.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
LAB price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
30TH FLOOR
NEW YORK, NY 10017
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| EXEL | Director | 928,906 | $64.58 | $59.99M | $0 | 2 | 2025-06-02 |
| LQDA | Director | 8,138,951 | $38.86 | $316.28M | $5.95M | 6 | 2024-09-12 |
| LAB | 10%+ Owner | 8,467,920 | $0.65 | $5.50M | $9.90M | 6 | 2023-07-03 |
| AMAG PHARMACEUTICALS, INC. (AMAG) Delisted | 10%+ Owner | 0 | — | — | $0 | 1 | 2020-11-17 |
Recent Filings
15 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-06-02 | EXEL | Grant (A) | — | $0 | EDGAR |
| 2024-09-12 | LQDA | Grant (A) | +2,247,190 | $20.00M | EDGAR |
| 2024-09-04 | LQDA | Mixed | −6,881,896 | $0 | EDGAR |
| 2023-07-03 | LAB | Other (J) | −1,558,690 | $0 | EDGAR |
| 2023-06-21 | LQDA | Grant (A) | — | $0 | EDGAR |
| 2023-06-02 | EXEL | Grant (A) | +36,352 | $0 | EDGAR |
| 2022-12-30 | LAB | Other (J) | −2,868,037 | $0 | EDGAR |
| 2022-09-07 | LQDA | Buy (P) | +500,000 | $2.81M | EDGAR |
| 2022-06-06 | LAB | Buy (P) | +900,000 | $1.76M | EDGAR |
| 2022-05-26 | LQDA | Buy (P) | +158,800 | $539.9K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.